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Abstract
Introduction: Taking consecutive antibiotic use into account is of importance to obtain insight in treatment within
disease episodes, use of 2nd- and 3rd-choice antibiotics, therapy failure and/or side effects. Nevertheless, studies
dealing with consecutive antibiotic use are scarce. We aimed at evaluating switch patterns in antibiotic use in the
outpatient setting in the Netherlands.
Methods: Outpatient antibiotic dispensing data was processed to antibiotic treatment episodes consisting of single
prescriptions or consecutive prescriptions (2006 to 2014). Consecutive prescriptions were categorised into prolongations
and switches. Switches were further analysed to obtain antibiotic switch percentages and trends over time. Outcomes
were compared with recommendations of Dutch guidelines.
Results: A total of 43,179,867 antibiotic prescriptions were included in the analysis, consisting of single prescriptions (95%)
, prolongations (2%) and switches (3%). The highest switch percentages were found for trimethoprim (7.6%)
and nitrofurantoin (5.4%). For fosfomycin, ciprofloxacin, flucloxacillin and trimethoprim we found the highest
yearly increase in switching. Amoxicillin/clavulanic acid was most often used as second antibiotic in a switch.
A surprisingly high number of 2nd- and 3rd-choice antibiotics are prescribed as first antibiotic in a treatment.
Conclusions: Although the actual reason for a switch is unknown, switch patterns can reveal problems
concerning treatment failure and guideline adherence. In general, switch percentages of antibiotics in the
Netherlands are low. The data contributes to the knowledge regarding antibiotic switch patterns in the
outpatient setting.
Keywords: Antibacterials, Antibiotic prescription, Antibiotic usage, Antibiotics, Consecutive antibiotic use,
Outpatient setting, Switch, Antibiotic failure, Treatment failure
* Correspondence: Loek.dejong@radboudumc.nl
1Department of Pharmacy, Radboud University Medical Center, Radboud
Institute for Health Sciences, P.O. Box 9101, 6500 HB Nijmegen, the
Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jong et al. BMC Infectious Diseases           (2019) 19:84 
https://doi.org/10.1186/s12879-019-3732-x
Introduction
The medical impact and economic burden of antibiotic
resistance is tremendous and increasing annually [1].
Antibiotic resistance is a direct result of antibiotic (mis)use
and therefore appropriate use of antibiotics is of utmost
importance [2]. Approximately 80–90% of total human
antibiotic consumption occurs in the outpatient setting [3–
5]. Collecting data on outpatient antibiotic use is essential
for adjusting practice to ensure appropriate use of antibi-
otics. Published reports concerning antimicrobial drug use
and resistance offer insight in trends and, therefore, play a
major role in policymaking [3–7].
A wide variety of indicators exist in literature to quantify
and qualify antimicrobial use, without consensus on the
most appropriate indicators to be used [8–10]. Overall,
quality indicator analyses consider each antibiotic prescrip-
tion as an individual course and do not take consecutive
antibiotic use into account. Patients might need more than
one prescription during an infectious disease episode. The
treatment strategy can change, or be extended due to
inadequate symptom resolution, results of antimicrobial
susceptibility tests, allergies, adverse drug reactions, thera-
peutic noncompliance, or as a result of an initially wrong
diagnosis.
To retrieve reliable results on consecutive antibiotic
use, the index date of the antibiotic and the duration of
the therapy have to be well documented and a unique
patient identifier is needed. Therefore only databases
containing high quality prescription or dispensing data
are suitable for the analysis of consecutive antibiotic use
in the outpatient setting.
So far, only a few studies deal with consecutive anti-
biotic use [11–14]. These studies focus on specific indi-
cations [11, 12], individual antibiotics [13], or specific
patient groups [14]. The main outcome in these studies
is treatment failure, defined as a refill of the index anti-
biotic dispensed after the completed days of therapy
(prolongation), a prescription of a different antibiotic
within one month after the index prescription (switch),
hospitalization, or a visit to the emergency department.
It has been shown that the vast majority of treatment
failures include antibiotic switches [11, 12].
Besides calculating treatment failure for individual
antibiotics, it is of great interest to visualize antibiotic
switches and focus on second prescriptions within an
antibiotic treatment. It is of importance whether 2nd/
3rd choice antibiotics are prescribed as first one, which
is often inappropriate, or as second one within an infec-
tious disease episode, which could be appropriate for
severe infections, or to treat pathogens resistant to the
1st choice antibiotic. Therefore, studies dealing with
consecutive antibiotic use can provide valuable insight.
We aimed at evaluating switch patterns in antibiotic use
in the outpatient setting in the Netherlands.
Methods
Data collection
Data on outpatient antibiotic use in the Netherlands was
obtained from the Foundation for Pharmaceutical Statistics
(SFK) for the period 2006–2014. The SFK collects dispens-
ing data from participating Dutch community pharmacies.
The participation rate increased from 90% in 2006 to 95%
in 2014. The dataset contained a pharmacy number, a
unique patient number, the anatomical therapeutic
chemical classification code (ATC-5) of the drug [15], the
start date, prescribed dose and the number of dispensed
units. In the Netherlands, the exact number of drug units
to complete the prescribed course is dispensed at the
pharmacy.
Study population
The study population consists of all patients who filled a
prescription for oral antibiotics (ATC J01) at a SFK
participating Dutch community pharmacy from January
1, 2006 to December 31, 2014. As the SFK covers 95% of
pharmacies, the study population is a proper representa-
tive of the Dutch population.
Data handling and classification
SFK data, provided in Microsoft Office Excel® 2007, was
processed to SPSS statistics 22 and organised per year. Only
antibiotics for systemic use (ATC-code J01) were included.
All antibiotic prescriptions were sorted by patient number.
A stop date for each prescription was calculated using the
start date, the number of dispensed units and the pre-
scribed dose, resulting in the duration of the course. The
total duration of antibiotic therapy for all patients was cal-
culated for each successive year. The antibiotic treatment
episodes were composed of single prescriptions and
consecutive prescriptions. A consecutive prescription was
defined as a successive antibiotic prescription for the same
patient within the period from prescribing the first anti-
biotic up to 3 days after the calculated end date of the first
antibiotic prescription. Consecutive prescriptions were fur-
ther categorised as prolongation, or switch. A prolongation
was defined as a repeat prescription of the same antibiotic,
and a switch was defined as a consecutive prescription with
another antibiotic.
Prescriptions for one patient with the same start date,
single antibiotic prescriptions with a duration > 14 days
and patients with an annual exposure to antibiotics of
more than 8 weeks were excluded (Fig. 1).
Data analyses
Analysis of the data was performed using Microsoft Of-
fice Excel® 2007 and SPSS statistics 22. We first counted
the total number of single prescription-, prolongation-
and switched treatment episodes per year. Next we cal-
culated the percentage of prolongations and switches by
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dividing the number of prolongations and switches by the
total number of treatment episodes. Data were presented
for the nine most often prescribed antibiotics, representing
> 90% of all antibiotic prescriptions. The other antibiotics
were grouped as others. The yearly switch percentage for
each antibiotic was calculated and plotted in a graph to
display trends over time. The yearly distribution of secondly
used antibiotics in a switch were displayed in a stacked
clustered column chart. A Sankey diagram was created
using the open source web tool RAWGraphs® [16] to
visualise the most common antibiotic switches in the year
2014.
Statistical analyses
Statistics were conducted with IBM SPSS Statistics 22. For
each year from 2006 to 2014, we determined antibiotic
switch rates for the nine most often prescribed antibiotics.
Generalised linear models with a binomial family and an
identity link were used to evaluate whether the linear
trends were statistically significant. To assess an associ-
ation between year and the distribution of second used
antibiotics we performed a chi-square test.
Results
The vast majority of antibiotic treatments concerned
single prescriptions (95%). Numbers and distribution of
antibiotic treatment episodes per year are shown in
Table 1. Antibiotic treatment episodes consisted for 2%
of prolongations and for 3% of switches.
The distribution of single prescriptions, prolongations
and switches for the nine most common used antibiotics
is shown in Table 2 for the year 2014. This table also
shows the number of antibiotics that were used as sec-
ond in a switch.
Trimethoprim and nitrofurantoin showed relatively
high switch percentages of 7.6 and 5.4% in 2014. In
Fig. 1 Overview of data handling
Jong et al. BMC Infectious Diseases           (2019) 19:84 Page 3 of 8
other words, a high percentage of initial prescriptions of
these drugs were followed by a second antibiotic pre-
scription. The switch percentages for the other antibi-
otics were between 2 and 4%. The time-trend from 2006
to 2014 in yearly switch percentages (from the first given
antibiotic) is shown in Fig. 2. Differences in switch
percentages over this period were minimal. The highest
yearly increase in switch percentage was found for fosfo-
mycin (0.09%/year), ciprofloxacin (0.08%/year), flucloxa-
cillin (0.05%/year) and trimethoprim (0.04%/year). On
the other hand, switching to a second antibiotic after ini-
tial use of doxycycline (− 0.08%/year), azithromycin and
clarithromycin (− 0.04%/year) and sulfamethoxazole/tri-
methoprim (− 0.04%/year) declined over time [data not
shown].
Figure 3 shows time-trends in the distribution of the
second antibiotic used in a switch. Amoxicillin/clavula-
nic acid was most often used as second antibiotic in a
switch. This finding is consistent over time. A clear
increase was seen for switches in which fosfomycin and
ciprofloxacin were used as second antibiotic.
Figure 4 is an overview of all switches (n = 1,414,747) in
the year 2014. In this figure the most common switch
patterns can be seen at a glance. For nitrofurantoin these
concerned switches to fosfomycin (24%), ciprofloxacin
(23%), trimethoprim (17%) or amoxicillin/clavulanic acid
(17%). Switches after first use of amoxicillin most often go
to one of the macrolides, azithromycin and clarithromycin
(31%), amoxicillin/clavulanic acid (25%) or doxycycline
(19%).
Discussion
Principal findings
To the best of our knowledge, this is the first study giv-
ing an overview of all first and second prescriptions
within antibiotic treatment episodes from a national
database of outpatient antibiotic use. The vast majority
of antibiotics, including antibiotics that are generally
considered as second- or third-choice treatments, are
prescribed as first antibiotic in a treatment. This finding
indicates that the initial choice of the prescriber is not
always in line with recommendations in guidelines.
Comparison with literature
Previously conducted studies regarding consecutive anti-
biotic use report high treatment failure rates [11, 12]. A
Table 2 Distribution of first and second used antibiotics in the year 2014
Antibiotic agent Single prescriptions
n (% of total)
Prolongations
n (% of total)
First used in a switch (drug A)a
n (% of total)
Second used in a switch (drug B)a
n (% of total)
amoxicillin 1,044,483 (24%) 18,924 (20%) 27,376 (18%) 12,264 (8%)
nitrofurantoin 717,571 (16%) 7922 (8%) 41,311 (27%) 8264 (5%)
amoxicillin/clavulanic acid 622,430 (14%) 22,259 (23%) 17,370 (11%) 33,862 (22%)
doxycycline 587,598 (13%) 8735 (9%) 17,699 (12%) 11,333 (7%)
azithromycin and clarithromycin 412,609 (9%) 7561 (8%) 9438 (6%) 24,079 (16%)
flucloxacillin 263,599 (6%) 13,871 (15%) 9931 (7%) 3515 (2%)
ciprofloxacin 233,127 (5%) 6168 (6%) 8131 (5%) 19,968 (13%)
pheneticillin 134,071 (3%) 1890 (2%) 5530 (4%) 991 (1%)
trimethoprim 72,794 (2%) 987 (1%) 6084 (4%) 8729 (6%)
fosfomycin 87,252 (2%) 844 (1%) 3129 (2%) 13,203 (9%)
others 208,017 (5%)b 6038 (6%)c 6568 (4%)d 16,359 (11%)e
total 4,383,551 (100%) 95,199 (100%) 152,567 (100%) 152,567 (100%)
a Switches: drug A ➔ drug B
b The group others consist of antibiotics representing ≤1% of total single prescriptions
c The group others largely consist of clindamycin, representing 2% of the total prolongations. All others represent ≤1% of total prolongations
d The group others consist of antibiotics representing ≤1% of the first ones used in a switch
e The group others largely consist of sulfamethoxazole/trimethoprim, clindamycin and norfloxacin, representing 3, 2 and 2% of the second ones used in a switch.
All other antibiotics represent ≤1% of the second ones used in a switch
Table 1 Total number of single prescriptions, prolongations and switches per year
2006 2007 2008 2009 2010 2011 2012 2013 2014 total Percentagea
single prescriptions 4,019,710 4,421,525 4,716,882 4,834,467 4,739,070 4,552,601 4,668,455 4,546,357 4,383,551 40,882,618 95%
prolongations 88,138 94,759 99,839 104,351 104,148 98,446 100,340 97,282 95,199 882,502 3%
switches 141,214 153,475 158,186 164,756 164,307 159,535 165,845 154,862 152,567 1,414,747 2%
total 4,249,062 4,669,759 4,974,907 5,103,574 5,007,525 4,810,582 4,934,640 4,798,501 4,631,317 43,179,867 100%
a Percentages were stable from 2006 to 2014
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study performed in the United States of America reports
unadjusted failure rates ranging from 20 to 24% for antibi-
otics prescribed for treatment of community-acquired
pneumonia [11]. A study from the United Kingdom reports
an overall treatment failure rate of 15% for antibiotics pre-
scribed for the treatment of upper and lower respiratory
tract infections, skin and soft tissue infections, and acute
otitis media [12]. The vast majority of treatment failures
include antibiotic switches as is demonstrated in the study
of Currie et al. reporting a switch in 94% of failures [12]. A
recent study from Norway reports an average switch rate of
6% for doxycycline, amoxicillin, phenoxymethylpenicillin
and macrolides [13]. A Danish study evaluated prescribing
patterns of antibiotics among Danish children and found
switch percentages of 5 and 1% for phenoxymethylpenicil-
lin and amoxicillin [14]. Although we cannot directly
compare our results with these data, due to different
settings and studies, differences in switch rates between
countries is apparent. Switch rates in the Netherlands
seems to be low in comparison with US, UK and Norway.
We found the highest switch percentages for trimetho-
prim and nitrofurantoin. These antibiotics are predomin-
antly used to treat urinary tract infections and the switch
percentages indicate that initial treatment with these antibi-
otics is quite often followed by another antibiotic. Accord-
ing to the Dutch national guidelines, nitrofurantoin is the
first choice treatment for uncomplicated urinary tract infec-
tions in the outpatient setting [17]. Fosfomycin should be
used as second choice and trimethoprim as third [17]. The
total use of nitrofurantoin significantly increased from 1.0
defined daily dose (DDD) /1000 inhabitant-days to 1.4
DDD/1000 inhabitant-days [5], and the switch percentage
Fig. 2 Analysis of antibiotic switch rate time trends using generalised linear models
Fig. 3 Time-trends in distribution of second used antibiotics in a switch. Pearson Chi-square test confirmed a relation between year and
distribution, p < .0001
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for nitrofurantoin showed a minor yearly increase. Tri-
methoprim showed a relatively high switch percentage of
7.6%. This might be explained by high resistance to tri-
methoprim among urine-isolated E. coli, K. pneumonia and
P. mirabilis, the predominant species causing urinary tract
infections in the Netherlands [5]. It was shown that fosfo-
mycin, trimethoprim and ciprofloxacin are often used as
second prescription after initial treatment with nitrofuran-
toin. This is in line with the Dutch guidelines for the treat-
ment of urinary infections [17]. However, the vast majority
of prescriptions for fosfomycin, trimethoprim and cipro-
floxacin concern first prescriptions in a treatment, which is
not in line with guidelines. A decrease in the switch per-
centage for sulfamethoxazole/trimethoprim is in line with a
decreasing resistance for this agent in the primary care set-
ting in the Netherlands [5]. In the Netherlands, presenta-
tion of urological indications has been increasing, with 148
episodes per 1000 patient-years in 2010; the prescribing
rate for urological indications remained about 50% [18].
For ciprofloxacin we found a yearly increase in total use
and a corresponding annual increase of 0.08% in its switch
percentage. This is worrisome as it could reflect increased
bacterial resistance to ciprofloxacin. Ciprofloxacin often is
a 3rd choice treatment in Dutch primary care and
reserved for severe infections and hospitalised patients,
and resistance in primary care jeopardises this aim.
Not surprisingly, amoxicillin/clavulanic acid is the drug
that is most often used as second antibiotic in a switch. It
is used after a wide variety of first prescriptions, including
nitrofurantoin, amoxicillin, doxycycline, flucloxacillin, a
macrolide and ciprofloxacin. A second prescription of
either azithromycin or clarithromycin, amoxicillin/clavula-
nic acid or doxycycline after initial amoxicillin are all
plausible changes in treatment strategy.
Our data indicate that fosfomycin and ciprofloxacin
are increasingly used as second drug in an antibiotic
treatment course. This could be the result of high
switching from trimethoprim and nitrofurantoin and the
increase in cystitis episodes [18]. Treatment failure due
to resistance to first choice antibiotics could also be
(partly) responsible for this observation, however, as we
do not know the reason for a switch firm conclusions
cannot be drawn. The increase in fosfomycin being used
as a second agent might be the result of changes in the
Dutch guidelines for urinary tract infections. Since 2005
fosfomycin is considered the second option to treat cyst-
itis, making it plausible that fosfomycin use (as first and
second prescriptions) increases in the following years.
Strengths and limitations of the study
The main strength of the study is the use of a nationwide
database containing over 90% of total dispensed antibi-
otics. The use of a database containing pharmacy dispens-
ing data instead of prescription data results in more valid
estimations of consumed antibiotics. Because patients in
the Netherlands are often linked to one pharmacy, it is
possible to monitor subsequent antibiotic use based on
pharmacy data. A recent study showed that only 2% of
patients regularly switch between pharmacies [19]. In con-
trast to earlier antibiotic switch studies that report data on
Fig. 4 Sankey diagram of all antibiotic switches in the year 2014. Left side: the top-9 initial antibiotics that are followed by a second prescription
within an antibiotic treatment episode. Right side: the top-9 antibiotics that are used as second prescription in a switch. The group others on the
left side of the figure reflects 10% of the total switches, mainly consisting of pheneticillin (36%), fosfomycin (21%) and cotrimoxazole (14%). The
group others on the right side of the figure reflects 14% of second prescriptions in a switch. This group predominantly involves cotrimoxazole
(24%), flucloxacillin (17%) clindamycin (16%) and norfloxacin (14%)
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specific diagnoses, or specific groups of antibiotics [11–
13], our study gives an overview of the total outpatient
antibiotic use. The greatest value of our approach is the
analysis and visualisation of consecutive antibiotic use and
distinguishing between prolongations and switches. In
contrast to other studies that define switches as a pre-
scription of a new antibiotic within 1month after index
date [11–13], our study uses a calculated end date of the
first antibiotic to define antibiotic switches. The chance of
including treatment for new or unrelated infections
instead of prolonged treatment of the initial one is largely
reduced by this method. Furthermore, we excluded pa-
tients on (nearly) chronic antibiotics because these could
distort the data. In these patients antibiotics are mainly
used for the prevention of recurrent infections instead of
treating acute infectious disease episodes.
However, there are also limitations to our study that need
to be addressed. First, the indication for prescription was
not available. With the indication it would have been pos-
sible to specifically identify those switches that deviate from
national treatment guidelines. Second, the data only con-
tains outpatient pharmacy data. Data on treatment failures
leading to hospital admission, visits to the emergency
department, or antibiotics previously used in the hospital
setting were not available and could not be incorporated.
Finally, we were not able to determine the actual reason for
the antibiotic switches. Although we speculate that an anti-
biotic switch reflects ineffectiveness of the treatment, pos-
sibly as a result of bacterial resistance, there can be several
other explanations. Switches can also be a result of doctors’
behaviour (wrong diagnosis, inappropriate prescribing), pa-
tients’ behaviour (non-compliance, inappropriate expecta-
tions and re-counselling), or progression of the infection
itself (including complications), or availability of the results
of in vitro antimicrobial susceptibility testing. The evidence
linking antibiotic treatment failure and antibiotic resistance
is considered to be weak [20, 21]. Therefore, we cannot
expect that bacterial resistance is the major cause of treat-
ment failure and antibiotic switches.
Future challenges
The dataset could be enriched by linking pharmacy data
with clinical patient data, the antibiotic indication,
outcomes of antimicrobial susceptibility tests, clinical
outcomes and complications. However, there are security,
privacy and technical issues that need to be addressed
before such linking can be performed. Another challenge
is to study seasonal and demographic differences in switch
percentages for antibiotics. For European comparison
studies, we encourage others to also evaluate trends in
consecutive antibiotic use and switching patterns. These
issues can provide even more detailed information that
can help policymaking.
Conclusion
The vast majority of antibiotics are prescribed as single
courses, also antibiotics that are generally considered as
2nd- or 3rd-choice treatment. This is not in line with
current guidelines. Switch percentages of antibiotics are
low with an average percentage of 3%. The highest switch
percentages were found for trimethoprim and nitrofuran-
toin. The most common antibiotic switches are in line with
guideline recommendations. The data contributes to the
knowledge regarding antibiotic switch patterns in the
outpatient setting.
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